PsorX-LabDisk

Psoriasis and eczema are among the most common inflammatory skin diseases, yet the differential diagnosis of psoriasis versus eczema remains challenging in routine dermatopathology. Overlapping clinical features and histopathological uncertainty often lead to unclear results. 

This diagnostic uncertainty can directly influence treatment decisions. Modern targeted therapies, including biologics (e.g. Ustekinumab, Tralokinumab, Secukinumab, Dupilumab, Brodalumab, Guselkumab, Ixekizumab) and small-molecule inhibitors, are increasingly used in precision dermatology. However, incorrect diagnosis of these inflammatory skin diseases may result in untargeted treatment selection or reduced therapeutic response.

PsorX-LabDisk enables analysis from standard FFPE samples based on the gene expression of NOS2 and CCL27, providing an objective molecular layer for the differential diagnosis of psoriasis and eczema. It is designed as a diagnostic support tool for dermatopathology laboratories, integrating seamlessly into existing laboratory workflows. 

In a comparison involving 14 dermatopathologists, histopathological assessments showed only low to moderate agreement, especially in unclear cases. In contrast, the PsorX-LabDisk RT-qPCR assay maintained strong sensitivity and specificity, even in difficult cases, and may serve as a helpful molecular tool to improve diagnostic confidence alongside routine histopathology. 

Please read the whole publication here.